Material Agreements

Planet 13 Holdings Inc. entered into Warrant Agreement with Odyssey Transfer US Inc. valued at Warrant agreement governing terms of warrants sold in the offering (effective 2024-03-07).

“On March 7, 2024, the Company entered into a warrant agency agreement with the Company’s transfer agent, Odyssey Transfer US Inc. (“Odyssey”), which will also act as the warrant agent for the Company, setting forth the terms and conditions of the Warrants sold in the Offering (the “Warrant Agreement”).”

Planet 13 Holdings Inc. entered into Underwriting Agreement with unknown valued at Underwriting Agreement for the offering of shares and warrants (effective 2024-03-07).

“A copy of the Underwriting Agreement is filed as Exhibit 1.1 hereto and is incorporated into this Item 1.01 by reference.”

Next Technology Holding Inc. entered into Purchase Agreement with certain existing shareholders of Future Dao Group Holding Limited valued at $13,396,000 (effective 2024-03-01).

“On March 1,2024, WeTrade Group Inc., a Wyoming corporation (“WeTrade”), entered into that certain share purchase agreement (the “Purchase Agreement”) with certain existing shareholders (the “Sellers”)of Future Dao Group Holding Limited, an exempted company incorporated and existing under the laws of the Cayman Islands(the “Target”),pursuant to which WeTrade agrees to purchase from the Sellers indirectly through Next Investment Group Limited,a wholly-owned subsidiary of WeTrade (“Next Investment”), and the Sellers agree to sell to Next Investment, an aggregate of 2,000 ordinary shares (the “Purchased Shares”) of the Target (the “Transaction”) at a per share purchase price of $6,698 per share for an aggregate purchase price of $13,396,000 (the “Purchase Price”).”

Momentus Inc. entered into Securities Purchase Agreement with an investor (the "Investor") valued at approximately $4.0 million (effective 2024-03-04).

“On March 4, 2024, Momentus Inc., a Delaware corporation (“Momentus” or the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an investor (the “Investor”) for the purchase and sale to the Investor in a registered direct offering (the “Offering”) of (i) an aggregate of 1,320,000 shares of the Company’s Class A common stock, par value $0.00001 per share (the “Class A Stock”), at a purchase price of $0.865 per share of Class A Stock and one Warrant (as defined below), (ii) in lieu of Class A Stock, at the election of the Investor, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 3,304,280 shares of Class A Stock, at a purchase price of $0.86499 per Pre-Funded Warrant and one Warrant, and (iii) warrants to purchase 4,624,280 shares of Class A Stock (the “Warrants”).”

PennyMac Financial Services, Inc. entered into Series 2024-GT1 indenture supplement with qualified institutional buyers valued at $425 million (effective 2024-02-29).

“On February 29, 2024, PennyMac Financial Services, Inc. (the “Company”), through its indirect subsidiary, PNMAC GMSR ISSUER TRUST (the “Issuer Trust”), issued an aggregate principal amount of $425 million in secured term notes (the “2024-GT1 Notes”) to qualified institutional buyers under Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”).”

VNOM Sub, Inc. entered into Underwriting Agreement with Diamondback Energy, Inc. and J.P. Morgan Securities LLC, as representative of the several underwriters valued at $35.00 per share (effective 2024-03-05).

“On March 5, 2024, Viper Energy, Inc. (“Viper”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Diamondback Energy, Inc. (“Diamondback” or the “Selling Stockholder”) and J.P. Morgan Securities LLC, as representative of the several underwriters named therein (the “Underwriters”).”

Superior Drilling Products, Inc. entered into Agreement and Plan of Merger with Drilling Tools International Corporation, DTI Merger Sub I, Inc., DTI Merger Sub II, LLC (effective 2024-03-06).

“On March 6, 2024, Superior Drilling Products, Inc., a Utah corporation (the “ Company ” or “ we ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Drilling Tools International Corporation, a Delaware corporation (“ Parent ”), DTI Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (“ Merger Sub I ”), and DTI Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Parent (“ Merger Sub II ” and together with Merger Sub I, “ Merger Subs ”).”

PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (effective 2022-03-03).

“On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).”

Lunai Bioworks Inc. terminated License Agreement with Weird Science LLC (effective 2024-03-01).

“On March 1, 2024, Renovaro Inc. (the “Company”) received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly-owned subsidiary of the Company, dated February 16, 2018 (the “License Agreement”).”

Avinger Inc entered into Securities Purchase Agreement with Zylox-Tonbridge Medical Limited valued at up to an aggregate of $15 million (effective 2024-03-04).

“On March 4, 2024, in connection with the Strategic Collaboration, the Company and Zylox-Tonbridge Medical Limited, a wholly-owned subsidiary of Zylox-Tonbridge (the “Purchaser”), entered into a Securities Purchase Agreement (the “Purchase Agreement”), pursuant to which the Purchaser agreed to purchase, in two tranches, up to an aggregate of $15 million in shares of the Company’s common stock,”

Avinger Inc entered into Strategic Cooperation and Framework Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).

“on March 4, 2024, the Company and Zylox-Tonbridge also entered into a Strategic Cooperation and Framework Agreement in conjunction with the Initial Closing (the “Collaboration Agreement” and, together with the License Agreement, the “Strategic Collaboration”),”

Avinger Inc entered into License Agreement with Zylox-Tonbridge Medical Technology Co., Ltd. (effective 2024-03-04).

“On March 4, 2024, Avinger, Inc. (“Avinger” or the “Company”) entered into a License and Distribution Agreement (the “License Agreement”) with Zylox-Tonbridge Medical Technology Co., Ltd. (“Zylox-Tonbridge”) effective as of the Initial Closing (defined below),”

Orgenesis Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.3 million (effective 2024-03-03).

“On March 3, 2024, Orgenesis Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”), 2,272,719 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $1.03 per share (the “Shares”) and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $2.00 per share (collectively, the “Warrants”).”

Xtant Medical Holdings, Inc. amended Credit Agreements with MidCap Financial Trust and MidCap Funding IV Trust valued at $17,000,000 term facility and $17,000,000 revolving facility (effective 2024-03-07).

“On March 7, 2024 (the “Closing Date”), Xtant Medical Holdings, Inc. (the “Company”), as guarantor, and certain of its subsidiaries, Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc. and Surgalign SPV, Inc., as borrowers (collectively, the “Borrowers”), entered into (i) an Amended and Restated Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) with MidCap Financial Trust, in its capacity as agent, and the lenders from time to time party thereto, and (ii) an Amended and Restated Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Funding IV Trust, in its capacity as agent, and the lenders from time to time party thereto.”

C-Bond Systems, Inc entered into Promissory Note and Securities Purchase Agreement with 1800 Diagonal Lending LLC valued at $157,000 aggregate principal amount; funded $125,000 on March 4, 2023 (effective 2024-03-01).

“On March 1, 2024, C-Bond Systems, Inc. (the “Company”) executed a Promissory Note (“Note”) in favor of 1800 Diagonal Lending LLC (the “Investor”) in the aggregate principal amount of $157,000 (the “Principal”), and an accompanying Securities Purchase Agreement (“SPA”).”

Keurig Dr Pepper Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $3.0 billion aggregate principal amount (effective 2024-03-07).

“On March 7, 2024, Keurig Dr Pepper Inc. (the “Company”) issued $3.0 billion aggregate principal amount of senior unsecured notes, consisting of $350.0 million aggregate principal amount of Floating Rate Senior Notes due 2027 (the “Floating Rate Notes”), $750.0 million aggregate principal amount of 5.100% Senior Notes due 2027 (the “2027 Notes”), $750.0 million aggregate principal amount of 5.050% Senior Notes due 2029 (the “2029 Notes”), $500.0 million aggregate principal amount of 5.200% Senior Notes due 2031 (the “2031 Notes”) and $650.0 million aggregate principal amount of 5.300% Senior Notes due 2034 (the “2034 Notes” and, together with the 2027 Notes, the 2029 Notes, and the 2031 Notes, the “Fixed Rate Notes,” and together with the Floating Rate Notes, the “Notes”), pursuant to an indenture, dated as of March 7, 2024, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Base Indenture”), as supplemented by the First Supplemental Indenture theret”

SANUWAVE Health, Inc. amended Consent, Limited Waiver and Fifth Amendment to Note and Warrant Purchase Agreement with NH Expansion Credit Fund Holdings LP (effective 2024-03-06).

“On March 6, 2024, Sanuwave Health, Inc. (the “Company”) entered into a Consent, Limited Waiver and Fifth Amendment to Note and Warrant Purchase Agreement (the “Fifth Amendment”) with NH Expansion Credit Fund Holdings LP (the “Agent”) and the noteholders party thereto (the “Holders”).”

Rivulet Entertainment, Inc. entered into Asset Purchase Agreement with Rivulet Media, Inc. valued at 90,784,800 shares of common stock of the Company, $0.001 par value per share, and $10,069,000 (effective 2024-03-01).

“On March 1, 2024, Advanced Voice Recognition Systems, Inc., a Nevada corporation (“the Company”), and Rivulet Media, Inc., a Delaware corporation (Rivulet), collectively the Parties, entered into an Asset Purchase Agreement (the “Purchase Agreement")”

Clean Energy Technologies, Inc. entered into Agreement with FirstFire Global Opportunities Fund, LLC valued at $280,500 (effective 2024-03-04).

“On March 4, 2024, Clean Energy Technologies, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Agreement ”) with FirstFire Global Opportunities Fund, LLC, a Delaware limited liability company (the “ Buyer ”), pursuant to which the Company agreed to issue and sell to the Buyer a convertible promissory note of the Company in the principal amount of $280,500”

Q/C TECHNOLOGIES, INC. entered into Plan of Merger with MyMD New Jersey, MyMD Delaware (effective 2024-03-04).

“MyMD Pharmaceuticals, Inc., a New Jersey corporation (“MyMD New Jersey” or, prior to the Reincorporation (as defined below), the “Company”) merged with and into its wholly-owned subsidiary, MyMD Pharmaceuticals, Inc., a Delaware corporation (“MyMD Delaware” or, following the Reincorporation, the “Company”), with MyMD Delaware being the surviving corporation, pursuant to that certain Agreement and Plan of Merger, dated as of March 4, 2024, by and between MyMD New Jersey and MyMD Delaware (the “Plan of Merger”)”

AIRGAIN INC entered into Sales Agreement with Craig-Hallum Capital Group LLC valued at up to $5.0 million (effective 2024-03-06).

“On March 6, 2024, Airgain, Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Craig-Hallum Capital Group LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $5.0 million in “at the market” offerings through or to the Agent, as sales agent or principal.”

ALIMERA SCIENCES INC amended Seventh Amendment with SLR Capital Partners, LLC (effective 2024-03-06).

“On March 6, 2024, Alimera Sciences, Inc. (“Alimera”) entered into the Seventh Amendment (the “Amendment”) to its Loan and Security Agreement dated December 31, 2019, with SLR Capital Partners, LLC (“SLR”) as collateral agent, and the lenders party thereto”

CoreCivic, Inc. entered into Underwriting Agreement with Citizens JMP Securities, LLC, as representative of the underwriters valued at $500 million (effective 2024-03-05).

“On March 5, 2024, CoreCivic, Inc., a Maryland corporation (the “Company”), and the subsidiary guarantors of the Company named therein (the “Guarantors”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citizens JMP Securities, LLC, as representative of the underwriters listed on Schedule A thereto (the “Underwriters”), for the issuance and sale of $500 million aggregate principal amount of the Company’s 8.250% senior unsecured notes due 2029 (the “Notes”).”

RGC RESOURCES INC amended Note Modification Agreement with Atlantic Union Bank (effective 2024-03-06).

“Also, on March 6, 2024, Midstream entered into a Note Modification Agreement (the "Agreement") with the Bank related to the unsecured Promissory Note (the "Note") with an original principal amount of $8,000,000 dated November 1, 2021, as amended.”

RGC RESOURCES INC amended Sixth Amendment to Credit Agreement with Atlantic Union Bank (effective 2024-03-06).

“On March 6, 2024, RGC Midstream, LLC (“Midstream”), a wholly owned subsidiary of RGC Resources, Inc. (“Resources”), entered into the Sixth Amendment to Credit Agreement (the "Amendment") with Atlantic Union Bank (the "Bank").”

Viracta Therapeutics, Inc. amended Second Amendment (the “Second Amendment”) to the Loan and Security Agreement with Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC valued at $5.0 million (effective 2024-03-01).

“On March 1, 2024, the Company entered into a Second Amendment (the “Second Amendment”) to the Loan and Security Agreement by and among the Company and Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company, and Oxford Finance LLC, dated November 4, 2021, as previously amended, providing for a modification of the loan amortization period and a pro rata reduction in the prospective debt amortization schedule, in exchange for a partial prepayment of the term loan.”

Viracta Therapeutics, Inc. amended Amendment No. 1 (the “XOMA Amendment”) to the Royalty Purchase Agreement with XOMA (US) LLC valued at $5.0 million (effective 2024-03-04).

“On March 4, 2024, in connection with the entry into the Day One Amendment, the Company entered into an Amendment No. 1 (the “XOMA Amendment”) to the Royalty Purchase Agreement, dated as March 22, 2021, by and between the Company and XOMA (US) LLC, modifying the economic value-share under the Royalty Purchase Agreement, by which the Company has retained the right, under certain circumstances, to participate in a pre-commercialization, event-based milestone up to $5.0 million.”

Viracta Therapeutics, Inc. amended Amendment No. 1 (the “Day One Amendment”) to the License Agreement for RAF with Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc. valued at $5.0 million (effective 2024-03-04).

“On March 4, 2024, the Company entered into an Amendment No. 1 (the “Day One Amendment”) to the License Agreement for RAF, dated as of December 16, 2019, by and between the Company and Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutcs-1, Inc., to monetize a pre-commercialization, event-based milestone for $5.0 million to be received in March 2024, thereby reducing the milestone percentage under the agreement.”

WD 40 CO entered into Quota Purchase Agreement with M12 Participações Empresariais S.A. valued at approximately $6.9 million USD (effective 2024-03-04).

“On March 4, 2024 (“Closing Date”), WD-40 Holding Company Brasil Ltda. (“Buyer”), a wholly-owned subsidiary of WD-40 Company (“Company”), acquired all of the issued and outstanding capital stock of Brazilian distributor, Theron Marketing Ltda. (“Theron”), from M12 Participações Empresariais S.A. (“Seller”) in a cash-for-stock transaction. The approximate purchase price of $6.9 million USD is subject to a 90-day post closing adjustment.”

AMERICAN TOWER CORP /MA/ entered into Supplemental Indenture No. 5 with U.S. Bank Trust Company, National Association valued at $650.0 million aggregate principal amount of its 5.200% senior unsecured notes due 2029 and $650.0 m (effective 2024-03-07).

“The Company issued the Notes under an indenture dated as of June 1, 2022 (the "Base Indenture"), as supplemented by a supplemental indenture dated as of March 7, 2024 (the "Supplemental Indenture No. 5" and, together with the Base Indenture, the "Indenture"), each between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee").”

LAUREATE EDUCATION, INC. entered into Stock Purchase Agreement with ILM Investments Limited Partnership, Torreal Sociedad de Capital Riesgo S.A., Pedro del Corro García-Lomas, Ana Gómez Cuesta and José Diaz-Rato Revuelta valued at 2,606,507 shares at $12.62 per share, aggregate purchase price $32,894,118 (effective 2024-03-05).

“Effective March 5, 2024, Laureate Education, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with each of ILM Investments Limited Partnership, Torreal Sociedad de Capital Riesgo S.A., Pedro del Corro García-Lomas, Ana Gómez Cuesta and José Diaz-Rato Revuelta (each, a “Seller” and together, the “Sellers”), pursuant to which the Company agreed to purchase an aggregate of 2,606,507 shares of the Company’s common stock from the Sellers at a purchase price of $12.62 per share for an aggregate purchase price of $32,894,118 (the “Purchase Price”).”

Clarus Corp terminated Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto (effective 2024-02-29).

“Contemporaneous with the closing of the Sale Transaction (hereinafter defined), Clarus Corporation (the “Company”) directed $135,013,124 of the proceeds from the closing of the Sale Transaction to payoff any and all outstanding borrowings under that certain Amended and Restated Credit Agreement, dated April 18, 2022, by and among the Company, Black Diamond Retail, Inc., Black Diamond Retail – Alaska, LLC, Sierra Bullets, L.L.C. (“Sierra”), SKINourishment, LLC, Black Diamond Retail – Colorado, LLC, Black Diamond Retail – Montana, LLC, Black Diamond Retail – Wyoming, LLC, Barnes Bullets-Mona, LLC (“Barnes”), Black Diamond Retail – Oregon, LLC, Black Diamond Retail – Vermont, LLC (collectively with the Company, the “Borrowers”) and the other loan parties party thereto (together with the Borrowers, each a “Loan Party”, and collectively, the “Loan Parties”) and JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”) and the lenders party thereto (the “Amended and Res”

Mitesco, Inc. entered into a notes offering with Cavalry Fund, AJB and Mercer Street Capital valued at $50,000 of proceeds each.

“the Company entered into a lending agreements with each of three (3) of its historical institutional investors, Cavalry Fund, AJB and Mercer Street Capital (“the Lenders”). The notes provide $50,000 of proceeds each”

IMMUCELL CORP /DE/ amended Amending Agreement with Norbrook Laboratories Limited (effective 2024-03-04).

“On March 4, 2024, ImmuCell Corporation (the “Company”) entered into an Amending Agreement (the “Amendment”) with Norbrook Laboratories Limited (“Norbrook”), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the “Agreement”).”

CADIZ INC entered into Third Amendment to Credit Agreement and First Amendment to Security Agreement with HHC $ Fund 2012 (the "Heerema Lender"), an affiliate of Heerema International Group Services S.A. valued at aggregate principal amount of $20,000,000 (effective 2024-03-06).

“On March 6, 2024, Cadiz Inc. (the “Company,” “we,” “our,” and “us”) and our wholly-owned subsidiaries, Cadiz Real Estate LLC, ATEC Water Systems, LLC, and Octagon Partners LLC (collectively, the “Borrowers”), entered into a Third Amendment to Credit Agreement and First Amendment to Security Agreement (the “Third Amendment”) with HHC $ Fund 2012 (the “Heerema Lender”), an affiliate of Heerema International Group Services S.A. (“Heerema”)”

Perspective Therapeutics, Inc. entered into Placement Agency Agreement with Oppenheimer & Co. Inc. valued at 5.85% of the gross proceeds (effective 2024-03-04).

“The Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the “Placement Agency Agreement”), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the “Placement Agents”).”

Perspective Therapeutics, Inc. entered into Investment Agreement with certain accredited institutional investors valued at approximately $87.4 million (effective 2024-03-04).

“On March 4, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain accredited institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), 92,009,981 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for a purchase price of $0.95 per share, representing the closing price of the Common Stock on March 1, 2024.”

OMNICOM GROUP INC. entered into First Supplemental Indenture with Deutsche Bank Trust Company Americas valued at €600,000,000 aggregate principal amount of 3.700% Senior Notes due 2032 (effective 2024-03-06).

“On March 6, 2024, Omnicom Finance Holdings plc (the “Issuer”), a wholly owned indirect subsidiary of Omnicom Group Inc. (the “Guarantor”), closed its public offering of €600 million aggregate principal amount of 3.700% Senior Notes due 2032 (the “Notes”), which are fully and unconditionally guaranteed by the Guarantor.”

Bunge Global SA amended BFE European Revolving Credit Facility Agreement with Crédit Agricole Corporate and Investment Bank, as agent, and certain lenders valued at $1.75 billion (effective 2024-03-01).

“On March 1, 2024, Bunge Finance Europe B.V. (“ BFE ”), a wholly owned subsidiary of Bunge, exercised the accordion provision set forth in its existing unsecured $1.75 billion 3-year Revolving Credit Agreement (as amended, the “ BFE European Revolving Credit Facility Agreement ”) among BFE, as borrower, Crédit Agricole Corporate and Investment Bank, as agent, and certain lenders party thereto (the “ BFE Lenders ”) pursuant to an accordion increase certificate (the “ BFE Accordion Increase Certificate ”) and an amendment to the BFE European Revolving Credit Facility Agreement (the “ BFE First Amendment ”) in an aggregate amount of $1.75 billion (the “ Additional Commitments ”)”

Bunge Global SA terminated Terminated BLFC-JPM Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders valued at $1.95 billion (effective 2024-03-01).

“The BLFC-JPM Revolving Credit Agreement replaced an existing U.S. $1.95 billion 5-year First Amended and Restated Revolving Credit Agreement, dated as of June 21, 2023 (the “ Terminated BLFC-JPM Revolving Credit Agreement ”), among BLFC, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders party thereto that was scheduled to mature on July 16, 2026, which was terminated in accordance with its terms on March 1, 2024.”

Bunge Global SA entered into BLFC-JPM Revolving Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders valued at $3.2 billion (effective 2024-03-01).

“On March 1, 2024, Bunge Limited Finance Corp. (“ BLFC ”), a wholly owned subsidiary of Bunge Global SA (“ Bunge ”), entered into an unsecured $3.2 billion 5-year Revolving Credit Agreement (the “ BLFC-JPM Revolving Credit Agreement ”) among BLFC, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, Sumitomo Mitsui Banking Corporation, as syndication agent, Citibank, N.A. and Crédit Agricole Corporate and Investment Bank, as co-documentation agents and certain lenders party thereto”

Kinetic Seas Inc. entered into Connectivity Agreement with Zazo Inc valued at Two year agreement for 10G internet connectivity with 2 fiber optical connections (effective 2023-12-14).

“Effective December 14, 2023, Bellatora Inc (the "Company") and Zazo Inc, ("Zazo") entered into a two year agreement for Zazo to provide 10G internet connectivity with 2 fiber optical connections to the Company's Databank-ORD4 location in Oakbrook Illinois.”

Kinetic Seas Inc. entered into Master Services Agreement and Service Order with Databank Holdings Inc valued at Master Services Agreement and Service Order for server collocation services at Databank-ORD4 (effective 2023-12-14).

“Effective December 14, 2023, Bellatora Inc (the "Company") entered into a Master Services Agreement and Service Order with Databank Holdings Inc, ("Databank") provide the Company with server collocation services at their Databank-ORD4 location in Oakbrook Illinois.”

Kinetic Seas Inc. entered into Letter of Agency with Lightyear AI Inc valued at Letter of Agency for Lightyear to act as agent for communication service purposes (effective 2023-12-14).

“Effective December 14, 2023, Bellatora Inc (the "Company") entered into a Letter of Agency with Lightyear AI Inc ("Lightyear") for Lightyear to act as agent for the Company for the purposes of inspecting, coordinating, discussing, and arranging communication service on behalf of the Company.”

Kinetic Seas Inc. amended Promissory Note Agreement with Coral Investment Partners, LP. valued at Amendment to Promissory Note Agreement, including interest-only payments, conversion rights, and ben (effective 2023-12-14).

“Effective December 14, 2023, Bellatora, Inc., n/k/a Kinetic Seas Incorporated (the “Company”) and Coral Investment Partners, LP. (“Coral”) agreed to amend their Promissory Note Agreement in the following manner:”

SURF AIR MOBILITY INC. entered into Security Purchase Agreement with GEM Global Yield LLC SCS valued at up to $35,200,000 (effective 2024-03-01).

“On March 1, 2024, Surf Air Mobility, Inc. (the “Company”) entered into a security purchase agreement (the “SPA”) with GEM Global Yield LLC SCS (“GEM”).”

Sixth Street Lending Partners entered into Purchase Agreement with BofA Securities, Inc., as representative of the several initial purchasers valued at $600.0 million (effective 2024-03-04).

“On March 4, 2024, Sixth Street Lending Partners (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) by and among the Company, Sixth Street Lending Partners Advisers, LLC (the “Adviser”) and BofA Securities, Inc., as representative of the several initial purchasers named in Schedule 1 thereto (the “Initial Purchasers”), in connection with the issuance and sale of $600.0 million aggregate principal amount of the Company’s 6.500% Notes due 2029 (the “Notes”) in a private offering to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons in transactions outside the United States in reliance on Regulation S under the Securities Act.”

ARES STRATEGIC INCOME FUND entered into Contribution Agreement with ASIF Funding II, LLC (effective 2024-03-01).

“on March 1, 2024, the Fund, as transferor, and the Borrower, as transferee, entered into a Contribution Agreement (the “Contribution Agreement,” and together with the Scotiabank Funding Facility, the “Borrower Agreements”), pursuant to which the Fund will transfer to the Borrower certain originated or acquired loans and related assets (collectively, the “Loans”) from time to time.”

ARES STRATEGIC INCOME FUND entered into Scotiabank Funding Facility with The Bank of Nova Scotia valued at $750 million (effective 2024-03-01).

“On March 1, 2024, Ares Strategic Income Fund (the “Fund”) entered into a Credit Agreement (the “Scotiabank Funding Facility”) with ASIF Funding II, LLC, a wholly owned subsidiary of the Fund, as borrower (the “Borrower”), the Fund, as parent and servicer, the lenders from time to time parties thereto, the Bank of Nova Scotia, as administrative agent, U.S. Bank Trust Company, National Association, as collateral agent and collateral administrator, and U.S. Bank National Association, as custodian and document custodian, that (i) provides a facility amount of $750 million”

Xeris Biopharma Holdings, Inc. entered into Amended and Restated Credit Agreement with Hayfin Services LLP, as administrative agent valued at $200.0 million in term loans (effective 2024-03-05).

“On March 5, 2024, Xeris Biopharma Holdings, Inc. (the “Company”), Xeris Pharmaceuticals, Inc. (“Xeris Pharma”) and certain subsidiary guarantors of the Company entered into an Amended and Restated Credit Agreement and Guaranty (the “Amended and Restated Credit Agreement”) with the lenders from time to time parties thereto (the “New Lenders”) and Hayfin Services LLP, as administrative agent for the New Lenders”